8. Bibliografia

-Raveendran R. Tips and Tricks for Controlling Eczema. Immunol Allergy Clin North Am. 2019; 39:521-533.

-Brown S, Reynolds NJ. Atopic and non-atopic eczema. BMJ 2006; 332:584–8.

-Rożalski M, Rudnicka L, Samochocki Z. Atopic and Non-atopic Eczema. Acta Dermatovenerol Croat. 2016; 24:110-5).

-Ward S. Eczema and dry skin in older people: identification and management. Br J Community Nurs. 2005; 10:453-6.

-Neena V, Asokan N, Jose R, Sarin A. Prevalence of eczema among older persons: A population-based cross-sectional study. Indian J Dermatol Venereol Leprol. 2023; 89:426-430.

-de Vries CJ, de Witt-de Jong AW, Dirven-Meijer PC, Burgers JS, Opstelten W. [The Dutch College of General Practitioners practice guideline ‘Eczema’]. Ned Tijdschr Geneeskd. 2014; 158:A8009.

-Silverberg, NB. A practical overview of pediatric atopic dermatitis, part 1: Epidemiology and pathogenesis. Cutis 2016, 97, 267–271.

-Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017; 23(8 Suppl):S115-S123.

–Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. J Invest Dermatol. 2017; 137:26-30.

-Alenazi SD. Atopic dermatitis: a brief review of recent advances in its management. Dermatol Reports. 2023; 15:9678.

-Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. Am Fam Physician. 2020; 101:590-598.

-Sohn A, Frankel A, Patel RV, Goldenberg G. Eczema. Mt Sinai J Med. 2011; 78:730-9.

-Armengot-Carbo M, Hernández-Martín Á, Torrelo A. The role of filaggrin in the skin barrier and disease development. Actas Dermosifiliogr. 2015; 106:86-95.

-Furue M. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. Int J Mol Sci. 2020; 21:5382.

–Fania L, Moretta G, Antonelli F, Scala E, Abeni D, Albanesi C, Madonna S. Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets. Int J Mol Sci. 2022; 23:2684.

–Dębińska A. New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression. J Clin Med. 2021; 10:2506.

-Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 2021; 22:4130.

-David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pathophysiology. Adv Exp Med Biol. 2017; 1027:21-37.

-Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, Chen S, Trier AM, Xu AZ, Tripathi SV, Luo J, Gao X, Yang L, Hamilton SL, Wang PL, Brestoff JR, Council ML, Brasington R, Schaffer A, Brombacher F, Hsieh CS, Gereau RW 4th, Miller MJ, Chen ZF, Hu H, Davidson S, Liu Q, Kim BS. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. Cell. 2017; 171:217-228.

–Tsoi LC, Rodriguez E, Stölzl D, Wehkamp U, Sun J, Gerdes S, Sarkar MK, Hübenthal M, Zeng C, Uppala R, Xing X, Thielking F, Billi AC, Swindell WR, Shefler A, Chen J, Patrick MT, Harms PW, Kahlenberg JM, Perez White BE, Maverakis E, Gudjonsson JE, Weidinger S. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J Allergy Clin Immunol. 2020; 145:1406-1415.

-Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy. 2021; 76:2982-2997.

-Kaczmarska A, Kwiatkowska D, Skrzypek KK, Kowalewski ZT, Jaworecka K, Reich A. Pathomechanism of Pruritus in Psoriasis and Atopic Dermatitis: Novel Approaches, Similarities and Differences. Int J Mol Sci. 2023; 24:14734.

-Fassett MS, Braz JM, Castellanos CA, Salvatierra JJ, Sadeghi M, Yu X, Schroeder AW, Caston J, Munoz-Sandoval P, Roy S, Lazarevsky S, Mar DJ, Zhou CJ, Shin JS, Basbaum AI, Ansel KM. IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis. Sci Immunol. 2023; 8(88):eabi6887.

-Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019; 40:84-92.

–Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, Shimojo N, Tanaka A, Nakahara T, Nagao M, Hide M, Fujita Y, Fujisawa T, Futamura M, Masuda K, Murota H, Yamamoto-Hanada K; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018, The Japanese Society of Allergology, The Japanese Dermatology Association. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020; 69:356-369.

-Mandlik DS, Mandlik SK. Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. Immunopharmacol Immunotoxicol. 2021; 43:105-125.

-Salvati L, Cosmi L, Annunziato F. From Emollients to Biologicals: Targeting Atopic Dermatitis. Int J Mol Sci. 2021; 22:10381.

-Silverberg JI, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, Chavda R, Gabriel S, Patel KR, Singam V, Kantor R, Hsu DY, Cella D. Association of itch triggers with atopic dermatitis severity and course in adults. Ann Allergy Asthma Immunol. 2020; 125:552-559

–Ramírez-Marín HA, Silverberg JI.Differences between pediatric and adult atopic dermatitis. Pediatr Dermatol. 2022; 39:345-353.

-Tétart F, Joly P. Eczema in elderly people. Eur J Dermatol. 2020; 30:663-667.

–Vakharia PP, Chopra R, Silverberg JI. Systematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials. Am J Clin Dermatol. 2018; 19:15-22.

-Traidl S, Heinrich L, Siegels D, Rösner L, Haufe E, Harder I, Abraham S, Ertner K, Kleinheinz A, Schäkel K, Wollenberg A, Effendy I, Quist S, Asmussen A, Wildberger J, Weisshaar E, Wiemers F, Brücher JJ, Weidinger S, Schmitt J, Werfel T; TREATgermany Study Group. High recurrence rate of eczema herpeticum in moderate/severe atopic dermatitis -TREATgermany registry analysis. J Dtsch Dermatol Ges. 2023. doi: 10.1111/ddg.

–Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients with atopic dermatitis. Cutis. 2019; 104:174-177.

-Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. J Invest Dermatol. 2017; 137:26-30.

-Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY, Chiesa Fuxench ZC. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018; 121:340-347.

-Capucci S, Hahn-Pedersen J, Vilsbøll A, Kragh N. Impact of Atopic Dermatitis and Chronic Hand Eczema on Quality of Life Compared With Other Chronic Diseases. Dermatitis. 2020; 31:178-184.

-Hsieh BJ, Shen D, Hsu CJ, Chan TC, Cho YT, Tang CH, Chu CY. The impact of atopic dermatitis on health-related quality of life in Taiwan. J Formos Med Assoc. 2022; 121(1 Pt 2):269-277.

-Bawany F, Northcott CA, Beck LA, Pigeon WR. Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies. J Allergy Clin Immunol Pract. 2021; 9:1488-1500.

-Snyder AM, Brandenberger AU, Taliercio VL, Rich BE, Webber LB, Beshay AP, Biber JE, Hess R, Rhoads JLW, Secrest AM. Quality of Life Among Family of Patients with Atopic Dermatitis and Psoriasis. Int J Behav Med. 2023; 30:409-415. 

-Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, Berger TG, Bergman JN, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014; 70:338-51.

–Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, Kantor R, Hsu DY, Silverberg JI. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017; 177:1316-1321.

–Gerbens LA, Prinsen CA, Chalmers JR, Drucker AM, von Kobyletzki LB, Limpens J, Nankervis H, Svensson Å, Terwee CB, Zhang J, Apfelbacher CJ, Spuls PI; Harmonising Outcome Measures for Eczema (HOME) initiative. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2017; 72:146-163.

–Lacour JP. Les scores d’évaluation de la dermatite atopique: Outcome measures for atopic dermatitis. Ann Dermatol Venereol. 2020; 147(11S1):11S12-11S18.

–Paller AS, Tan JKL, Bagel J, Rossi AB, Shumel B, Zhang H, Abramova A. IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis. Br J Dermatol. 2022; 186:496-507.

–Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, Czarnecka-Operacz M, Schäfer T, Schmid-Grendelmeier P, Simon D, Szalai Z, Szepietowski JC, Taïeb A, Torrelo A, Werfel T, Ring J; European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018; 32:657-682.

-Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, Czarnecka-Operacz M, Schäfer T, Schmid-Grendelmeier P, Simon D, Szalai Z, Szepietowski JC, Taïeb A, Torrelo A, Werfel T, Ring J; European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018; 32:850-878.

-Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, Shimojo N, Tanaka A, Nakahara T, Nagao M, Hide M, Fujita Y, Fujisawa T, Futamura M, Masuda K, Murota H, Yamamoto-Hanada K; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018, The Japanese Society of Allergology, The Japanese Dermatology Association. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020; 69:356-369.

-Kulthanan K, Tuchinda P, Nitiyarom R, Chunharas A, Chantaphakul H, Aunhachoke K, Chularojanamontri L, Rajatanavin N, Jirapongsananuruk O, Vichyanond P, Chatchatee P, Sangsupawanich P, Wananukul S, Singalavanija S, Trakanwittayarak S, Rerkpattanapipat T, Thongngarm T, Wisuthsarewong W, Limpongsanurak W, Kamchaisatian W, Noppakun N. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pac J Allergy Immunol. 2021; 39:145-155.

-Saeki H, Ohya Y, Furuta J, Arakawa H, Ichiyama S, Katsunuma T, Katoh N, Tanaka A, Tsunemi Y, Nakahara T, Nagao M, Narita M, Hide M, Fujisawa T, Futamura M, Masuda K, Matsubara T, Murota H, Yamamoto-Hanada K. English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. J Dermatol. 2022; 49:e315-e375.

-Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic Dermatitis in Children and Adults -Diagnosis and Treatment. Dtsch Arztebl Int. 2023; 120:224-234.

-Micali G, Paternò V, Cannarella R, Dinotta F, Lacarrubba F. Evidence-based treatment of atopic dermatitis with topical moisturizers. G Ital Dermatol Venereol. 2018; 153:396-402.

–Yang YB, Gohari A, Lam J. Brief Academic Review and Clinical Practice Guidelines for Pediatric Atopic Dermatitis. Curr Pediatr Rev. 2021; 17:229-237.

–Tan SY, Chandran NS, Choi EC. Steroid Phobia: Is There a Basis? A Review of Topical Steroid Safety, Addiction and Withdrawal. Clin Drug Investig. 2021; 41:835-842.

-Sheary B, Harris MF. Cessation of Long-term Topical Steroids in Adult Atopic Dermatitis: A Prospective Cohort Study. Dermatitis. 2020; 31:316-320.

-Song SY, Jung SY, Kim E. Steroid phobia among general users of topical steroids: a cross-sectional nationwide survey. J Dermatolog Treat. 2019; 30:245-250.

-Haider Z, Proctor A, Moss C. Potency of topical steroids should be clearly labelled on all packaging. Br J Dermatol. 2023; 188:427-428.

–Oishi N, Iwata H, Kobayashi N, Fujimoto K, Yamaura K. A survey on awareness of the “finger-tip unit” and medication guidance for the use of topical steroids among community pharmacists. Drug Discov Ther. 2019; 13:128-132.

–Krafchik BR. The use of topical steroids in children. Semin Dermatol. 1995; 14:70-4.

-Pariser DM. Topical steroids: a guide for use in the elderly patient. Geriatrics. 1991; 46:51-4; Tétart F, Joly P. Eczema in elderly people. Eur J Dermatol. 2020; 30:663-667.

-Singh PK, Singh G. Relative Potency of Topical Corticosteroid Preparations. Indian J Dermatol Venereol Leprol. 1985; 51:309-312.

–Harvey J, Lax SJ, Lowe A, Santer M, Lawton S, Langan SM, Roberts A, Stuart B, Williams HC, Thomas KS. The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review. Skin Health Dis. 2023; 3:e268.

-Furue M, Terao H, Moroi Y, Koga T, Kubota Y, Nakayama J, Furukawa F, Tanaka Y, Katayama I, Kinukawa N, Nose Y, Urabe K. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J Dermatol. 2004; 31:277-83.

–Kleinman E, Laborada J, Metterle L, Eichenfield LF. What’s New in Topicals for Atopic Dermatitis? Am J Clin Dermatol. 2022; 23:595-603.

-Wallace DV. Treatment options for moderate to severe atopic dermatitis. Allergy Asthma Proc. 2022; 43:474-493.

-Deleuran M, Dézfoulian B, Elberling J, Knutar I, Lapeere H, Lossius AH, Schuttelaar MLA, Stockman A, Wikström E, Bradley M, de Bruin-Weller M, Gutermuth J, Mandelin JM, Schmidt MC, Thyssen JP, Vestergaard C. Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. J Eur Acad Dermatol Venereol. 2023. doi: 10.1111/jdv.19512.

-Koskeridis F, Evangelou E, Ntzani EE, Kostikas K, Tsabouri S. Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis. J Cutan Med Surg. 2022; 26:613-621.

–Ghazal S, Ridha Z, D’Aguanno K, Nassim D, Quaiattini A, Netchiporouk E, Poulin Y, Kalia S, Marcoux D, Piguet V, Jack C. Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II. Front Med (Lausanne). 2022; 9:821871.

–Hamp A, Hanson J, Schwartz RA, Lambert WC, Alhatem A. Dupilumab-associated mycosis fungoides: a cross-sectional study. Arch Dermatol Res. 2023; 315:2561-2569.

–Hamp A, Hanson J, Alhatem A, Schwartz RA. Dupilumab-Associated Sezary Syndrome. Indian J Dermatol. 2023; 68:459-462.

–Boesjes CM, Van der Gang LF, Zuithoff NPA, Bakker DS, Spekhorst LS, Haeck I, Kamsteeg M, De Graaf M, De Bruin-Weller MS. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry. Acta Derm Venereol. 2023; 103:adv00872.

–Boesjes CM, van der Gang LF, Bakker DS, Ten Cate TA, Spekhorst LS, de Graaf M, van Dijk MR, de Bruin-Weller MS. Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis. JAMA Dermatol. 2023:e233849. doi: 10.1001.

–Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021; 184:437-449.

-Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, Hijnen D, Jensen TN, Bang B, Olsen CK, Kurbasic A, Weidinger S; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021; 184:450-463.

-Blair HA. Tralokinumab in Atopic Dermatitis: A Profile of Its Use. Clin Drug Investig. 2022; 42:365-374).

–Serra López-Matencio JM, Morell Baladrón A, Castañeda S. JAK-STAT inhibitors for the treatment of immunomediated diseases. Med Clin (Barc). 2019; 152:353-360.

–Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021; 148:927-940; Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022; 71:40-46.

–Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021; 148:927-940.

–Simpson EL, Kircik L, Blauvelt A, Kallender H, Kuo Y, Ren H, Sturm D, Eichenfield LF. Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator’s Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy. J Dermatol. 2023. doi: 10.1111.

–Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Schmitt J, Flohr C. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. JAMA Dermatol. 2022; 158:523-532.

-Wilken B, Zaman M, Asai Y. Patient education in atopic dermatitis: a scoping review. Allergy Asthma Clin Immunol. 2023; 19:89

-Sedeh FB, Henning MAS, Jemec GBE, Ibler KS. Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2022; 102:adv00764.

–Drucker AM, Lam M, Elsawi R, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Schmitt J, Flohr C. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2023:ljad393).

-Antonelli F, Malvaso D, Caldarola G, Simone C, Peris K, Chiricozzi A. Infectious adverse events in patients with atopic dermatitis treated with baricitinib. Immunotherapy. 2023. doi: 10.2217.

-Calle Sarmiento PM, Chango Azanza JJ. Dyshidrotic Eczema: A Common Cause of Palmar Dermatitis. Cureus. 2020; 12:e10839.

-Stuckert J, Nedorost S. Low-cobalt diet for dyshidrotic eczema patients. Contact Dermatitis. 2008; 59:361-5.

–Voland P, Barthel C, Azzouz B, Raison-Peyron N, Du-Thanh A, Staumont-Sallé D, Jachiet M, Soria A, Nosbaum A, Valois A, Leleu C, Lebrun-Vignes B, Trenque T, Hettler D, Bernier C, Viguier M; French Group of Research and Study in Atopic Eczema (GREAT) of the French Society of Dermatology. Intravenous and subcutaneous immunoglobulins-associated eczematous reactions occur with a broad range of immunoglobulin types: A French national multicenter study. J Am Acad Dermatol. 2023; 88:380-387.

–Bose R, Beecker J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report. SAGE Open Med Case Rep. 2020; 8:2050313X20904561.

-Gladys TE, Maczuga S, Flamm A. Characterizing demographics and cost of care for dyshidrotic eczema. Contact Dermatitis. 2022; 86:107-112.

-Vocks E, Plötz SG, Ring J. The Dyshidrotic Eczema Area and Severity Index – A score developed for the assessment of dyshidrotic eczema. Dermatology. 1999; 198:265-9.

-Nishizawa A. Dyshidrotic Eczema and Its Relationship to Metal Allergy. Curr Probl Dermatol. 2016; 51:80-5.

–Tchernev G, Zanardelli M, Voicu C, Bakardzhiev I, Lotti T, Lotti J, França K, Batashki A, Wollina U. Impetiginized Dyshidrotic Eczema. Open Access Maced J Med Sci. 2017; 5:539-540.

–Haft MA, Park HH, Lee SS, Sprague JM, Paller AS, Cotton CH, Thyssen JP, Eichenfield LF. Diagnosis and Management of Pediatric Chronic Hand Eczema: The PeDRA CACHES Survey. Paediatr Drugs. 2023; 25:459-466.

-Li Y, Xiao J, Sun Y, Fang H, Qiao J. Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review. J Asthma Allergy. 2023; 16:1-8.

-Lee SD, Ahn HJ, Shin MK. Nine cases of chronic hand and foot eczema treated with baricitinib. Australas J Dermatol. 2023; 64:408-412).

-Aoyama H, Tanaka M, Hara M, Tabata N, Tagami H. Nummular eczema: An addition of senile xerosis and unique cutaneous reactivities to environmental aeroallergens. Dermatology. 1999; 199:135-9.

–Jiamton S, Tangjaturonrusamee C, Kulthanan K. Clinical features and aggravating factors in nummular eczema in Thais. Asian Pac J Allergy Immunol. 2013; 31:36-42.

–Robinson CA, Love LW, Farci F. Nummular Dermatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.2022 Oct 3.

–Böhner A, Jargosch M, Müller NS, Garzorz-Stark N, Pilz C, Lauffer F, Wang R, Roenneberg S, Zink A, Thomas J, Theis FJ, Biedermann T, Eyerich S, Eyerich K. The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant T(H)2/T(H)17 immune response. J Allergy Clin Immunol. 2023; 152:408-419.

-Hüppop F, Dähnhardt-Pfeiffer S, Fölster-Holst R. Characterization of Classical Flexural and Nummular Forms of Atopic Dermatitis in Childhood with Regard to Anamnestic, Clinical and Epidermal Barrier Aspects. Acta Derm Venereol. 2022; 102:adv00664.

–Bonamonte D, Foti C, Vestita M, Ranieri LD, Angelini G. Nummular eczema and contact allergy: a retrospective study. Dermatitis. 2012. 23:153-7.

–Silverberg JI, Hou A, Warshaw EM, Maibach HI, Belsito DV, DeKoven JG, Zug KA, Taylor JS, Sasseville D, Fransway AF, DeLeo VA, Pratt MD, Reeder MJ, Atwater AR, Fowler JF Jr, Zirwas MJ, Marks JG Jr. Prevalence and trend of allergen sensitization in patients with nummular (discoid) eczema referred for patch testing: North American Contact Dermatitis Group data, 2001-2016. Contact Dermatitis. 2021; 85:46-57.

-McWhirter S, Foster R, Halbert A, Miller R, Morgan VA, Rademaker M, Robertson S, Scardamaglia L, Warren L, Wong LC, Zappala T, Orchard D. Discoid (nummular) eczema in the paediatric setting – An Australian/New Zealand narrative. Australas J Dermatol. 2022; 63:e289-e296.

-Niculet E, Bobeica C, Tatu AL. Glucocorticoid-Induced Skin Atrophy: The Old and the New. Clin Cosmet Investig Dermatol. 2020; 13:1041-1050.

-Tavecchio S, Angileri L, Pozzo Giuffrida F, Germiniasi F, Marzano AV, Ferrucci S. Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients. J Clin Med. 2020; 9:2684.

–Ju T, Van der Does A, Mohsin N, Yosipovitch G. Lichen Simplex Chronicus Itch: An Update. Acta Derm Venereol. 2022;102:adv00796)

–Rajalakshmi R, Thappa DM, Jaisankar TJ, Nath AK. Lichen simplex chronicus of anogenital region: a clinico-etiological study. Indian J Dermatol Venereol Leprol. 2011; 77:28-36.

-Juan CK, Chen HJ, Shen JL, Kao CH. Lichen Simplex Chronicus Associated With Erectile Dysfunction: A Population-Based Retrospective Cohort Study. PLoS One. 2015; 10:e0128869.

-Thorstensen KA, Birenbaum DL. Recognition and management of vulvar dermatologic conditions: lichen sclerosus, lichen planus, and lichen simplex chronicus. J Midwifery Womens Health. 2012; 57:260-75.

-Stewart KM. Clinical care of vulvar pruritus, with emphasis on one common cause, lichen simplex chronicus. Dermatol Clin. 2010; 28:669-80.

-Chibnall R. Vulvar Pruritus and Lichen Simplex Chronicus. Obstet Gynecol Clin North Am. 2017; 44:379-388.

-Muylaert BPB, Borges MT, Michalany AO, Scuotto CRC. Lichen simplex chronicus on the scalp: exuberant clinical, dermoscopic, and histopathological findings. An Bras Dermatol. 2018; 93:108-110.

-Ju T, Vander Does A, Yosipovitch G. Scalp dysesthesia: a neuropathic phenomenon. J Eur Acad Dermatol Venereol. 2022; 36:790-796.

–Fernández Armenteros JM, Molinero Ponce I, Castan Campanera E, Casanova Seuma JM. Perfiles psicológicos de los pacientes con psicodermatosis. PIEL. Formación continuada en dermatología 2016; 31:15-23

-Lotti T, Buggiani G, Prignano F. rurigo nodularis and lichen simplex chronicus. Dermatol Ther. 2008; 21:42-6.

-Mercan S, Altunay IK, Demir B, Akpinar A, Kayaoglu S. Sexual dysfunctions in patients with neurodermatitis and psoriasis. J Sex Marital Ther. 2008; 34:160-8.

-An JG, Liu YT, Xiao SX, Wang JM, Geng SM, Dong YY. Quality of life of patients with neurodermatitis. Int J Med Sci. 2013; 10:593-8.

–Thürlimann W. Neurodermitis atopica. Ther Umsch. 1989; 46:111-7.

-Lynch PJ. Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region. Dermatol Ther. 2004; 17:8-19.

-Starace M, Iorizzo M, Mandel VD, Bruni F, Misciali C, Apalla Z, Silyuk T, Pellacani G, Patrizi A, Piraccini BM, Alessandrini A. Scalp dysaesthesia and lichen simplex chronicus: diagnostic and therapeutic update with literature review. Clin Exp Dermatol. 2022; 47:3-8.

-Juarez MC, Kwatra SG. A systematic review of evidence based treatments for lichen simplex chronicus. J Dermatolog Treat. 2021; 32:684-692.

–Schmitt J, Abraham S, Trautmann F, Stephan V, Fölster-Holst R, Homey B, Bieber T, Novak N, Sticherling M, Augustin M, Kleinheinz A, Elsner P, Weidinger S, Werfel T. Einsatz und Wirksamkeit von Systemtherapien bei Erwachsenen mit schwerer Neurodermitis: Erste Ergebnisse des deutschen Neurodermitis-Registers TREATgermany. J Dtsch Dermatol Ges. 2017; 15:49-60.

–Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Kahle J, Kapp A, Nemat K, Peters E, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Traidl-Hoffmann C, Werner R, Wollenberg A, Worm M, Ott H. Aktualisierung Systemtherapie bei Neurodermitis zur S2k-Leitlinie Neurodermitis. J Dtsch Dermatol Ges. 2021; 19:151-1699.

-Saint-Mezard P, Rosieres A, Krasteva M, Berard F, Dubois B, Kaiserlian D, Nicolas JF. Allergic contact dermatitis. Eur J Dermatol. 2004; 14:284-95.

-Scheinman PL, Vocanson M, Thyssen JP, Johansen JD, Nixon RL, Dear K, Botto NC, Morot J, Goldminz AM. Contact dermatitis. Nat Rev Dis Primers. 2021; 7:38.

–Kodumudi V, Feng H. Contact dermatitis and nutrition. Clin Dermatol. 2022; 40:145-149.

-Elmas ÖF, Akdeniz N, Atasoy M, Karadag AS. Contact dermatitis: A great imitator. Clin Dermatol. 2020; 38:176-192.

-Bains SN, Nash P, Fonacier L. Irritant Contact Dermatitis. Clin Rev Allergy Immunol. 2019; 56:99-109.

-Li Y, Li L. Contact Dermatitis: Classifications and Management. Clin Rev Allergy Immunol. 2021; 61:245-281.

-Drewitz KP, Stark KJ, Zimmermann ME, Heid IM, Apfelbacher CJ. Frequency of hand eczema in the elderly: Cross-sectional findings from the German AugUR study. Contact Dermatitis. 2021. doi: 10.1111/cod.13920.

-Romijn-Bucarciuc D, Maessen GC, Visch MB. Handeczeem en hygiënemaatregelen. Ned Tijdschr Tandheelkd. 2021; 128:323-330.

-Lund TT, Ebbehøj NE, Agner T. Hand eczema and wet work. Ugeskr Laeger. 2020; 182:V05200393.

-Lampel HP, Powell HB. Occupational and Hand Dermatitis: a Practical Approach. Clin Rev Allergy Immunol. 2019; 56:60-71.

-Lushniak BD. Occupational contact dermatitis. Dermatol Ther. 2004; 17:272-7.

-Papadatou Z, Williams H, Cooper K. Effectiveness of interventions for preventing occupational irritant hand dermatitis: a quantitative systematic review. JBI Database System Rev Implement Rep. 2018; 16:1398-1417.

-Loman L, Uter W, Armario-Hita JC, Ayala F, Balato A, Ballmer-Weber BK, Bauer A, Bircher AJ, Buhl T, Czarnecka-Operacz M, Dickel H, Fuchs T, Giménez Arnau A, John SM, Kränke B, Kręcisz B, Mahler V, Rustemeyer T, Sadowska-Przytocka A, Sánchez-Pérez J, Scherer Hofmeier K, Schliemann S, Simon D, Spiewak R, Spring P, Valiukevičienė S, Wagner N, Weisshaar E, Pesonen M, Schuttelaar; ESSCA Working Group. European Surveillance System on Contact Allergies (ESSCA): Characteristics of patients patch tested and diagnosed with irritant contact dermatitis. Contact Dermatitis. 2021. doi: 10.1111/cod.13833.

-Madan I, Parsons V, Ntani G, Coggon D, Wright A, English J, McCrone P, Smedley J, Rushton L, Murphy C, Cookson B, Williams HC. A behaviour change package to prevent hand dermatitis in nurses working in the National Health Service: results of a cluster randomized controlled trial. Br J Dermatol. 2020; 183:462-470.

-Ale IS, Maibach HI. Irritant contact dermatitis. Rev Environ Health. 2014; 29:195-206.

-Humphrey S, Bergman JN, Au S. Practical management strategies for diaper dermatitis. Skin Therapy Lett. 2006; 11:1-6).

-Lima AL, Timmermann V, Illing T, Elsner P. Contact Dermatitis in the Elderly: Predisposing Factors, Diagnosis, and Management. Drugs Aging. 2019; 36:411-417.

-Di Altobrando A, La Placa M, Neri I, Piraccini BM, Vincenzi C. Contact dermatitis due to masks and respirators during COVID-19 pandemic: What we should know and what we should do. Dermatol Ther. 2020; 33:e14528.

-Landow K. Hand dermatitis. The perennial scourge. Postgrad Med. 1998; 103:141-2, 145-8, 151-2.

-Tan SW, Oh CC. Contact Dermatitis from Hand Hygiene Practices in the COVID-19 Pandemic. Ann Acad Med Singap. 2020; 49:674-676.

–Kostner L, Anzengruber F, Guillod C, Recher M, Schmid-Grendelmeier P, Navarini AA. Allergic Contact Dermatitis. Immunol Allergy Clin North Am. 2017; 37:141-152.

-Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF. Allergic and irritant contact dermatitis. Eur J Dermatol. 2009; 19:325-32.

–Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010; 82:249-55.

–Gupta S, Pruthi S, Kumar A, Mahendra A. Common Contact Allergens in Patients with Chronic Vesicular Dermatitis of Palms and Soles: A Retrospective Study. Indian Dermatol Online J. 2019; 10:396-400.

-Ahlström MG, Thyssen JP, Wennervaldt M, Menné T, Johansen JD. Nickel allergy and allergic contact dermatitis: A clinical review of immunology, epidemiology, exposure, and treatment. Contact Dermatitis. 2019; 81:227-241.

-Özkaya E, Aslan MSE. Occupational allergic contact dermatitis: a 24-year, retrospective cohort study from Turkey. Contact Dermatitis. 2021. doi: 10.1111/cod.13938.

-Tresukosol P, Swasdivanich C. Hand contact dermatitis in hairdressers: clinical and causative allergens, experience in Bangkok. Asian Pac J Allergy Immunol. 2012; 30:306-12.

-Zeerak S, Shah IH, Akhtar S, Bashir Y, Bhat MA, Jeelani S, Bhat YJ, Rather S, Devi R. Clinical Pattern and Patch Test Profile of Hand Eczema in Hospital Employees in a Tertiary Care Hospital of North India. Indian Dermatol Online J. 2021; 12:72-77.

-Zirwas MJ. Contact Dermatitis to Cosmetics. Clin Rev Allergy Immunol. 2019; 56:119-128.

-Nassau S, Fonacier L. Allergic Contact Dermatitis. Med Clin North Am. 2020; 104:61-76.

-Kodumudi V, Feng H. Contact dermatitis and nutrition. Clin Dermatol. 2022; 40:145-149.

-Veien NK. Systemic contact dermatitis. Int J Dermatol. 2011; 50:1445-56.

-Aquino M, Rosner G. Systemic Contact Dermatitis. Clin Rev Allergy Immunol. 2019; 56:9-18.

-Pigatto P, Martelli A, Marsili C, Fiocchi A. Contact dermatitis in children. Ital J Pediatr. 2010; 36:2.

-Belloni Fortina A, Caroppo F, Tadiotto Cicogna G. Allergic contact dermatitis in children. Expert Rev Clin Immunol. 2020; 16:579-589.

-Valderrama Arnay S, Morales Tirado A, López de Haro de Torres J. Dermatitis por contacto. Protoc diagn ter pediatr. 2019; 2:177-84.

-Seth D, Poowuttikul P, Kamat D, Pansare M. Contact Dermatitis in Children. Pediatr Ann. 2021; 50:e198-e205.

-Sharma AD. Low nickel diet in dermatology. Indian J Dermatol. 2013; 58:240.

–Piérard GE, Quatresooz P. What do you mean by eczema craquelé? Dermatology. 2007; 215:3-4.

–Cassler NM, Burris AM, Nguyen JC. Asteatotic eczema in hypoesthetic skin: a case series. JAMA Dermatol. 2014; 150:1088-90.

-Caproni M, Torchia D, Pestelli E, Volpi W, Fabbri P, Schincaglia E. Clinical and immunohistochemical study of the effect of a cosmetic product in patients with asteatotic eczema. Int J Tissue React. 2005; 27:23-9.

–Akimoto K, Yoshikawa N, Higaki Y, Kawashima M, Imokawa G. Quantitative analysis of stratum corneum lipids in xerosis and asteatotic eczema. J Dermatol. 1993; 20:1-6.

–Specht S, Persaud Y. Asteatotic Eczema. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.2023 Jul 4.

–Chu CH, Chou CY, Lin FL. Generalized eczema craquelé (asteatotic dermatitis) associated with pemetrexed treatment. J Eur Acad Dermatol Venereol. 2016; 30:e81-e83.

-Harries L, Traidl S, Klespe KC, Werfel T. Altersekzeme und deren Therapie. Dermatologie (Heidelb). 2023; 74:678-686.

-de Vries CJ, de Witt-de Jong AW, Dirven-Meijer PC, Burgers JS, Opstelten W. NHG-standaard ‘Eczeem’. Ned Tijdschr Geneeskd. 2014; 158:A8009.

–Schulz P, Bunselmeyer B, Bräutigam M, Luger TA. Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol. 2007; 21:90-4.

-Sundaresan S, Migden MR, Silapunt S. Stasis Dermatitis: Pathophysiology, Evaluation, and Management. Am J Clin Dermatol. 2017; 18:383-390.

-Payne D. Venous eczema: more than just a rash. Br J Community Nurs. 2023; 28:298-300.

–Lindemayr H, Drobil M. Unterschenkelekzem und Kontaktallergie. Hautarzt. 1985; 36:227-31.

-Yosipovitch G, Nedorost ST, Silverberg JI, Friedman AJ, Canosa JM, Cha A. Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol. 2023; 24:275-286.

-Barron GS, Jacob SE, Kirsner RS. Dermatologic complications of chronic venous disease: medical management and beyond. Ann Vasc Surg. 2007; 21:652-62; Morton LM, Phillips TJ. Venous eczema and lipodermatosclerosis. Semin Cutan Med Surg. 2013; 32:169-76.

-Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: Photoallergic and phototoxic reactions. Clin Dermatol. 2016; 34:571-81.

-Di Bartolomeo L, Irrera N, Campo GM, Borgia F, Motolese A, Vaccaro F, Squadrito F, Altavilla D, Condorelli AG, Motolese A, Vaccaro M. Drug-Induced Photosensitivity: Clinical Types of Phototoxicity and Photoallergy and Pathogenetic Mechanisms. Front Allergy. 2022; 3:876695.

-Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 2011; 34:821-37.

-Kim WB, Shelley AJ, Novice K, Joo J, Lim HW, Glassman SJ. Drug-induced phototoxicity: A systematic review. J Am Acad Dermatol. 2018; 79:1069-1075.

-Epaulard O, Leccia MT, Blanche S, Chosidow O, Mamzer-Bruneel MF, Ravaud P, Thiebaut A, Villier C, Lortholary O. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect. 2011; 41:639-45.

-Sibaud V. Anticancer treatments and photosensitivity. J Eur Acad Dermatol Venereol. 2022; 36 (Suppl 6):51-58.

-Ferrer Guillén B, Giácaman MM, Valenzuela Oñate C, Magdaleno Tapial J, Hernández Bel P, Pérez Ferriols A. Pirfenidone-induced photosensitivity confirmed by pathological phototest. Photodiagnosis Photodyn Ther. 2019; 25:103-105.

-Jeong SH, Hong EH, Park EJ, Kim KJ, Kim KH. A Case of Pirfenidone-Induced Photosensitive Drug Eruption. Ann Dermatol. 2023; 35(Suppl 1):S48-S51.

-Montgomery S, Worswick S. Photosensitizing drug reactions. Clin Dermatol. 2022; 40:57-63.

-Hofmann GA, Weber B. Drug-induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences. J Dtsch Dermatol Ges. 2021; 19:19-29.

-Klelemen H, Hancu G, Kacsó E, Papp LA. Photosensitivity Reactions Induced by Photochemical Degradation of Drugs. Adv Pharm Bull. 2022; 12:77-85.

-Pinto AR, Machado Cunha I, Rebelo Gomes E. Fig Tree-Induced Phytophotodermatitis: A Case Report on the Perils of a Hobby. Cureus. 2023; 15:e41888.

-Harshman J, Quan Y, Hsiang D. Phytophotodermatitis: Rash with many faces. Can Fam Physician. 2017; 63:938-940.

–Son JH, Jin H, You HS, Shim WH, Kim JM, Kim GW, Kim HS, Ko HC, Kim MB, Kim BS. Five Cases of Phytophotodermatitis Caused by Fig Leaves and Relevant Literature Review. Ann Dermatol. 2017; 29:86-90.

-Morris AJ, Rueckeis CA. Sap and Sun: A Case of Phytophotodermatitis. Wilderness Environ Med. 2023; 34:532-535.

-Fu PP, Xia Q, Zhao Y, Wang S, Yu H, Chiang HM. Phototoxicity of herbal plants and herbal products. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013; 31:213-55.

-Petit R, Izambart J, Guillou M, Guedes Da Silva Almeida J, Gonçalves de Oliveira Junior R, Sol V, Ouk TS, Grougnet R, Quintans-Junior L, Sitarek P, Thiéry V, Picot L. A review of phototoxic plants, their phototoxic metabolites, and possible developments as photosensitizers. Chem Biodivers. 2023; 20:e202300494.

-Esser PR, Mueller S, Martin SF. Plant Allergen-Induced Contact Dermatitis. Planta Med. 2019; 85:528-534.

-Moloney FJ, Parnell J, Buckley CC. Iatrogenic phytophotodermatitis resulting from herbal treatment of an allergic contact dermatitis. Clin Exp Dermatol. 2006; 31:39-41.

-Lankerani L, Baron ED. Photosensitivity to exogenous agents. J Cutan Med Surg. 2004; 8:424-31.

-Wilm A, Berneburg M. Photoallergy. J Dtsch Dermatol Ges. 2015; 13:7-12.

–Loh TY, Cohen PR. Ketoprofen-induced photoallergic dermatitis. Indian J Med Res. 2016; 144:803-806.